| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | TPCA-1 | CTRPv2 | pan-cancer | AAC | 0.031 | 0.3 |
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | 0.034 | 0.3 |
| mRNA | Nutlin-3 | CTRPv2 | pan-cancer | AAC | 0.033 | 0.3 |
| mRNA | itraconazole | CTRPv2 | pan-cancer | AAC | -0.036 | 0.3 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | SRT-1720 | CTRPv2 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.033 | 0.3 |
| mRNA | ceranib-2 | CTRPv2 | pan-cancer | AAC | -0.031 | 0.3 |